Sep 17, 2024
Tilburg, 17 September 2024 – Treeway is pleased to announce the successful completion of patient enrollment for the Phase 2A ASURE study. The study is the first randomized, double-blind, placebo-controlled trial aiming to evaluate the safety,...
Aug 28, 2023
Singapore, August 28th, 2023 –Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS)¹ – the most...
Mar 6, 2023
Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial...
Nov 9, 2021
Barcelona, November 9th, 2021 – Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has today announced the next major milestone in its mission to develop transformative therapies...
Oct 20, 2021
Barcelona and Tilburg, 20 October 2021 – Today, Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, announced they have entered...
May 29, 2018
–Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated– Rotterdam, The Netherlands, May 29th2018 – Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announced...
